Maximum Treatment Interval With Aflibercept T&E

Sponsor
Shin Kong Wu Ho-Su Memorial Hospital
Study ID
NCT05342857
Status
Unknown

Conditions

  • Neovascular Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the duration of effectiveness of anti-VEGF (Aflibercept) by analyzing the percentage of patients whose maximum treatment interval is extended to 16 weeks and beyond in 24 months and their long-term remission.

Key Dates

Start date
Jan 1, 2022
Status verified
Apr 2022
Primary completion
Aug 31, 2024
Completion
Apr 30, 2025

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

The percentage of patients whose maximum treatment interval is extended to 24 months [ Time Frame: 2 years ]

Central Contacts

Related Studies